AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01081275 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CI Therapy
Description: CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
Study NCT01081275 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAM treatments
Description: CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
Study NCT01337206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting with ELLA Biodegradable stent
Description: Treating benign esophageal lesions with the placement of a degradable stent
Study NCT01337206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dilations
Description: Treating benign esophageal lesions with standard dilation therapy
Study NCT02737423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Effect of Vitamin D on the symptoms of diabetic neuropathy
Study NCT04206085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viveve - Active
Description: Radiofrequency and Cryogen-Cooling
Study NCT04206085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viveve - Cryogen-Alone
Description: Cryogen-Cooling
Study NCT04206085 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Viveve - Sham
Description: Sham
Study NCT01791777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare Coaching
Description: This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.
Study NCT04258657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel-albumin and S-1
Description: neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
Study NCT00725543 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
Study NCT03329729 — intervention group
Intervention type: OTHER
Intervention: Rosuvastatin
Description: Hyperlipidemic patients treated with rosuvastatin
Study NCT01128114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate (Seroquel XR)
Description: Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
Study NCT00020761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.
Study NCT00020761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks.
Study NCT02803099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number-SR15-63-Z13-084).
Study NCT02391077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Foreskin disinfection with Povidone-Iodine
Study NCT02391077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic topical cream
Description: Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
Study NCT02391077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 1%
Description: Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
Study NCT01309698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (LAF237)
Study NCT01309698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose
Study NCT01309698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Voglibose
Study NCT02578498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate intake
Description: Carbohydrate intake \< 50 gram
Study NCT03121794 — intervention group
Intervention type: DEVICE
Intervention: ultrasound machine
Description: Regular ultrasound machine used at Cleveland Clinic
Study NCT04685096 — intervention group
Intervention type: OTHER
Intervention: Test product creme
Description: twice daily application of creme containing 2% NMN
Study NCT04685096 — intervention group
Intervention type: OTHER
Intervention: Reference creme
Description: twice daily application of reference creme
Study NCT01615159 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior and lifestyle counseling
Description: 20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
Study NCT03564132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yigansan
Description: Yigansan granules
Study NCT03564132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
Study NCT00921206 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAX102
Description: 1 ug i.m. compared to 2 ug s.c.
Study NCT01017601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seneca Valley virus-001
Description: Given IV
Study NCT01017601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study NCT03850990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo pill and no placebo pill
Description: The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.
Study NCT02578498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low carbohydrate intake
Description: Carbohydrate intake > 250 gram
Study NCT01810276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 400 mL of Saline will be given intravenously over 2 hours once
Study NCT01810276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelets
Description: 2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
Study NCT04697654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC19
Description: Hydroxychloroquine Liposome Inhalation Suspension
Study NCT04697654 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: TLC19 Vehicle
Description: Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)
Study NCT00768885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision 1
Description: Currently marketed PureVision soft contact lens.
Study NCT00768885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureVision 2
Description: Alternate design soft contact lens.
Study NCT02083302 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SCREAM Theater Dose 1
Description: Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
Study NCT02083302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREAM Theater Dose 1
Description: Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
Study NCT02083302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREAM Theater Doses 2 & SCREAM Theater Dose 3
Description: Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention.
Study NCT02083302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREAM Theater Dose 4
Description: Booster Session
Study NCT02578888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Therapy
Description: Palliative Therapy
Study NCT02578888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Palliative Therapy
Study NCT02578888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Therapy + idiographic
Description: Ancillary studies
Study NCT01607346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezogabine/retigabine
Description: Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
Study NCT05180565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colovac
Description: A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
Study NCT00675337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineum maintained
Description: infants maintained at the level of the perineum until umbilical cord clamping
Study NCT00675337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal placement
Description: infants placed on the maternal abdomen prior to umbilical cord clamping
Study NCT00560898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
Study NCT00560898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
Study NCT00560898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
Study NCT00560898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
Study NCT02731170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
Study NCT01331135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
Study NCT03782532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT03782532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT03782532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Controller Therapies (include prednisone/prednisolone)
Description: Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral
Study NCT03782532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Controller Therapies (include prednisone/prednisolone)
Description: Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral
Study NCT03782532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Reliever Therapies
Description: Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled
Study NCT03782532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Reliever Therapies
Description: Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled
Study NCT00913770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI)
Description: Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
Study NCT00913770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Initiation
Study NCT02888275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02888275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Study NCT03949738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Near-infrared spectroscopy-based assessement of cerebral autoregulation.
Description: Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation.
Study NCT00351936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Study NCT00351936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03033927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CTC isolocation and analysis
Description: Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
Study NCT02950038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg given by mouth daily in a 28 day cycle.
Study NCT02950038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
Study NCT02903420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
Study NCT04140084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-life clinical meetings
Description: Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
Study NCT01072578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
Study NCT01072578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
Study NCT01523327 — intervention group
Intervention type: OTHER
Intervention: measuring protein creatinin ratio,serum uric acid
Description: A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method.
Study NCT03522207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: polysomnography
Description: BASELINE PSG Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
Study NCT03522207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 100 mg trazodone or placebo given once 30 minutes prior to 2nd PSG
Study NCT03522207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo per os 30 minutes prior to 2nd PSG
Study NCT03522207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: polysomnography
Description: 2nd psg, done 1 week after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
Study NCT03522207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 100 mg trazodone per os 30 minutes prior to 3rd PSG
Study NCT03522207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebos
Description: 100 mg placebo per os 30 minutes prior to 3rd PSG
Study NCT03522207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: polysomnography
Description: 3rd PSG, done 2 weeks after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
Study NCT02946021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head and neck garments for pneumatic compression device
Description: Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
Study NCT02946021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIRFLI with ICG
Description: Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
Study NCT01954199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurodynamic Group
Description: All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.~* In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;~* In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;~* In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner.
Study NCT02578888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy + idiographic
Description: Ancillary studies